Sandoz Reports Growth in Sales and Upgraded Margin Guidance

Sandoz Group AG has announced its financial results for the first nine months of 2025, reporting net sales of USD 8,057 million, an increase of 5% at constant currencies. The company's ten best-selling medicines grew by 9%, contributing 34% of total net sales. Notably, biosimilars exceeded 30% of net sales for the first time.

Regional growth was observed across all areas: Europe's sales rose by 6%, the International market increased by 4%, and North America experienced a 1% rise. Several product launches, including Wyost and Jubbonti, have bolstered sales. Looking ahead, Sandoz has raised its full-year EBITDA margin guidance to 21-22%, reflecting confidence in continued growth driven by biosimilars.

Sandoz also announced a settlement with Regeneron over a biosimilar, allowing market entry for a biosimilar version of Eylea in late 2026. Challenges in penicillin production remain due to US-China trade tensions, prompting calls for sustainable European supply solutions.